DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in enabling these infants to consume peanuts freely after treatment. Participants will use the patch daily for 36 months, followed by an oral peanut challenge to determine their tolerance and potential peanut consumption for the next year. This trial could lead to early, non-invasive allergy treatment for young children, potentially changing the course of peanut allergies.
Robbins LLP is investigating Beta Bionics, Inc.'s officers and directors for potential violations of securities laws and breaches of fiduciary duties following the company's announcement of weaker-than-expected patient growth. Beta Bionics reported a...
Robbins LLP is investigating whether officers and directors of Simulation Plus, Inc. violated securities laws and breached fiduciary duties following significant stock price drops in 2025. The company faced a 24% stock decline after lowering revenue ...
Canada is in a technical recession with economic contraction in three of the last four quarters, the worst among G7 nations. Entrepreneur Yanik Guillemette criticizes Ottawa's weak leadership and decision paralysis, which erodes business confidence a...
The Canadian Animal Health Institute (CAHI) awarded its 2026 Industry Leadership Award to the Honourable Don Boudria for his efforts in advancing animal health policy and strengthening the sector's voice in Ottawa. Dr. Arman Panah of Virbac received ...
Associated Capital Group, Inc. announced that its 2026 Annual Meeting of Shareholders has been rescheduled from June 3 to July 8, 2026, at 4:15 pm Eastern Time in Greenwich, Connecticut. The Board of Directors set June 3, 2026, as the new record date...
